The main target in the case of SCCHN is the epidermal growth factor receptor (EGFR).The hyperexpression of epidermal growth factor receptors is noted in approximately90–100% of cases of squamous-cell oropharyngeal cancer and is associated withthe worst prognosis of the disease, a low differentiation of the tumor, and adecrease in the total and recurrence-free survival rates [15–17]. The gene discussed is EGFR; the disease is neoplasm.